Text Size

An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00109148
First received: April 22, 2005
Last updated: January 23, 2012
Last verified: January 2012
History of Changes
  Purpose

The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with obesity (considerably overweight).


Condition Intervention Phase
Obesity
 Drug: MK0364
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Study to Assess the Safety and Efficacy of MK0364 in Obese Patients

Resource links provided by NLM:

MedlinePlus related topics: Obesity
U.S. FDA Resources

Further study details as provided by Merck:

Enrollment: 500
Study Start Date: July 2004
Study Completion Date: February 2005
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who are obese (considerably overweight) based on body mass index.

Exclusion Criteria:

  • Patients with serious or unstable current or past medical conditions
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00109148

Sponsors and Collaborators
Merck
Investigators
Study Director: Medical Monitor Merck
  More Information

No publications provided by Merck

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck Sharp & Dohme Corp
ClinicalTrials.gov Identifier: NCT00109148     History of Changes
Other Study ID Numbers: MK-0364-006, 2005_011
Study First Received: April 22, 2005
Last Updated: January 23, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Merck:
Obesity and obesity-related medical conditions

Additional relevant MeSH terms:
Obesity
Overnutrition
Nutrition Disorders
 Overweight
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on May 22, 2013